| Clinical Trials | |
| Title: | Vaccine Trial for Melanoma Patients Whose Disease Has Metastasized (Stage IV). |
| Purpose: | The main purpose of the study is to determine the safety of the trial's experimental procedure and the maximum dose of the vaccine that a human can tolerate. A secondary purpose is to see if the experimental procedure causes the melanoma cancer to shrink. |
| Study Number: | 10432 |
| Number of Patients: | 9 |
| Elgibility: |
Patients may qualify if: ·They are age 18 or older with a diagnosis of melanoma that has metastasized to other parts of the body (but not the brain) [Stage IV]. ·There is presence of a melanoma tumor large enough (about 2 x 2 cm.) to be surgically removed for use in making the vaccine, and; ·Additional disease that can be evaluated/measured for response during the course of the trial. ·The patient is able to care for self and well enough to carry out light or sedentary activities. |
| Treatment: | A specially prepared vaccine will be injected into a lymph node on days one, 15 and 29 of the trial. If the disease has gotten better or not worsened, the patient may receive additional injections based on desire, clinical status and availability of vaccine. |
| Principal Investigator: | Joseph Clark, M.D. |
| Enrollment Phone: | (708) 327-3236 |